{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:48:29Z","timestamp":1790516909191,"version":"4.1.0"},"reference-count":47,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Voriconazole is a first-line agent for the treatment of invasive pulmonary aspergillosis. Isolates with elevated voriconazole MICs are increasingly being seen, and the optimal treatment regimen is not defined. We investigated whether the combination of voriconazole with anidulafungin may be beneficial for the treatment of<jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">A. fumigatus<\/jats:named-content>strains with elevated voriconazole MICs. We used an<jats:italic>in vitro<\/jats:italic>model of the human alveolus to define the exposure-response relationships for a wild-type strain (voriconazole MIC, 0.5 mg\/liter) and strains with defined molecular mechanisms of triazole resistance (MICs, 4 to 16 mg\/liter). All strains had anidulafungin minimum effective concentrations (MECs) of 0.0078 mg\/liter. Exposure-response relationships were estimated using galactomannan as a biomarker. Concentrations of voriconazole and anidulafungin were measured using high-performance liquid chromatography (HPLC). The interaction of voriconazole and anidulafungin was described using the Greco model. Fungal growth was progressively inhibited with higher drug exposures of voriconazole. Strains with elevated voriconazole MICs required proportionally greater voriconazole exposures to achieve a comparable antifungal effect. Galactomannan concentrations were only marginally reduced by anidulafungin monotherapy. An additive effect between voriconazole and anidulafungin was apparent. In conclusion, the addition of anidulafungin does not markedly alter the exposure-response relationship of voriconazole. A rise in serum galactomannan during combination therapy with voriconazole and anidulafungin should be interpreted as treatment failure and not attributed to a paradoxical reaction related to echinocandin treatment.<\/jats:p>","DOI":"10.1128\/aac.01111-12","type":"journal-article","created":{"date-parts":[[2012,7,24]],"date-time":"2012-07-24T04:37:37Z","timestamp":1343104657000},"page":"5180-5185","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":34,"title":["Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant Aspergillus fumigatus in an<i>In Vitro<\/i>Model of Invasive Pulmonary Aspergillosis"],"prefix":"10.1128","volume":"56","author":[{"given":"Adam R.","family":"Jeans","sequence":"first","affiliation":[{"name":"School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, National Institute for Health Research Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester National Health Service, and Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Howard","sequence":"additional","affiliation":[{"name":"School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, National Institute for Health Research Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester National Health Service, and Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Al-Nakeeb","sequence":"additional","affiliation":[{"name":"School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, National Institute for Health Research Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester National Health Service, and Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Goodwin","sequence":"additional","affiliation":[{"name":"School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, National Institute for Health Research Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester National Health Service, and Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Gregson","sequence":"additional","affiliation":[{"name":"School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, National Institute for Health Research Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester National Health Service, and Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Warn","sequence":"additional","affiliation":[{"name":"School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, National Institute for Health Research Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester National Health Service, and Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Hope","sequence":"additional","affiliation":[{"name":"School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, National Institute for Health Research Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester National Health Service, and Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.327-330.2001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/339324","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease","volume":"34","author":"Boutboul F","year":"2002","unstructured":"BoutboulF. 2002. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin. Infect. Dis. 34:939\u2013943.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.3001-3012.2002"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00958.x"},{"key":"e_1_3_2_6_2","volume-title":"Reference method for dilution antifungal susceptibility testing of filamentous fungi; approved standard","author":"Clinical Laboratory Sciences Institute","year":"2008","unstructured":"Clinical Laboratory Sciences Institute. 2008. Reference method for dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed, M38\u2013A2. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1232-1235.2005"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.970-978.2004"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2010.02.004"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1469-0691.2008.02086.x","article-title":"EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia\u2013forming moulds","volume":"14","author":"European Committee for Antimicrobial Susceptibility Testing","year":"2008","unstructured":"European Committee for Antimicrobial Susceptibility Testing. 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia\u2013forming moulds. Clin. Microbiol. Infect. 14:982\u2013984.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco WR","year":"1995","unstructured":"GrecoWR BravoG ParsonsJC. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331\u2013385.","journal-title":"Pharmacol. Rev."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020191"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.334"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00702-11"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1086\/510535","article-title":"Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy","volume":"195","author":"Hope WW","year":"2007","unstructured":"HopeWW. 2007. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J. Infect. Dis. 195:455\u2013466.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.3.2.263"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1086\/432069","article-title":"Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis","volume":"192","author":"Hope WW","year":"2005","unstructured":"HopeWW. 2005. Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. J. Infect. Dis. 192:673\u2013680.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1507.090043"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir023"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis372"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2564-2568.2002"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/505603"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02281-09"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.7.1480"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01586-09"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3697-3701.2005"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cncr.24022","article-title":"Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients","volume":"115","author":"Maertens J","year":"2009","unstructured":"MaertensJ. 2009. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 115:355\u2013362.","journal-title":"Cancer"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22348"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jac\/dkg242","article-title":"Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus","volume":"51","author":"Manavathu EK","year":"2003","unstructured":"ManavathuEK AlangadenGJ ChandrasekarPH. 2003. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J. Antimicrob. Chemother. 51:1423\u20131425.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/423380"},{"key":"e_1_3_2_31_2","volume-title":"Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis","author":"Marr KA","year":"2012","unstructured":"MarrKA. 2012. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis, abstr LB 2812. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1086\/511080","article-title":"When a paradoxical increase in serum galactomannan antigen during caspofungin therapy is not paradoxical after all","volume":"44","author":"Miceli MH","year":"2007","unstructured":"MiceliMH AnaissieEJ. 2007. When a paradoxical increase in serum galactomannan antigen during caspofungin therapy is not paradoxical after all. Clin. Infect. Dis. 44:757\u2013760. (Author's reply, 44:760\u2013761.)","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1086\/528714","article-title":"Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications","volume":"46","author":"Miceli MH","year":"2008","unstructured":"MiceliMH. 2008. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin. Infect. Dis. 46:1412\u20131422.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cid\/cir441","article-title":"Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition","volume":"53","author":"Nouer SA","year":"2011","unstructured":"NouerSA. 2011. Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin. Infect. Dis. 53:671\u2013676.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl392"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.3039-3041.2002"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01572-07"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.12-23.2002"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00329-09"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1086\/375420","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin","volume":"187","author":"Petraitis V","year":"2003","unstructured":"PetraitisV. 2003. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. 187:1834\u20131843.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3572-3574.2005"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000202421.94822.f7"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050219"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01083-10"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01556-08"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp355"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1086\/525258"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.6.3156-3163.2002"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01111-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01111-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T08:49:00Z","timestamp":1743842940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01111-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1128\/AAC.01111-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.01111-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"2012-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-09-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}